AGTC to Host Conference Call on November 11 at 8:00 am ET to Discuss XLRP 12-Month Data and Full 6-Month Data from Highest Dose Groups of its Ongoing Phase 1/2 Clinical Trial

Rhea-AI Summary

Applied Genetic Technologies Corporation (Nasdaq: AGTC) will release 12-month data from its Phase 1/2 clinical trial for X-linked Retinitis Pigmentosa (XLRP) on November 11, 2020. The data will evaluate the durability of effect and safety across multiple patient groups. A conference call will be held at 8:00 AM ET on the same day to discuss the findings. AGTC is focused on developing gene therapies for rare diseases, with active clinical trials for XLRP and other conditions, aiming to address significant unmet clinical needs.

Positive

• Upcoming release of 12-month clinical data on XLRP expected to provide insights into treatment safety and efficacy.
• AGTC positioned as a leader in AAV-based gene therapy for rare ophthalmic diseases.

Negative

• None.

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it plans to release 12-month data for Groups 1 through 4 evaluating durability of effect and continued safety and interim data of Groups 5 and 6 evaluating safety and efficacy at higher doses for its Phase 1/2 clinical trial in patients with X-linked Retinitis Pigmentosa (XLRP) on November 11, 2020. AGTC management will host a conference call and webcast with accompanying slides to review the data and provide a general update on the XLRP trial beginning at 8:00am Eastern Time on the same date.

The live webcast will be available in the Events and Presentations section of the Investor Relations page at http://ir.agtc.com/events-and-presentations. To access the call, dial 877-407-6184 (US) or 201-389-0877 (outside of the US). The archived webcast and slide presentation will be available in the Events and Presentations section of the Company's website.

About AGTC

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. The Company’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Its pre-clinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

IR/PR CONTACTS: 
David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485
david.carey@finnpartners.com or glenn.silver@finnpartners.com

Corporate Contacts:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728  
bsullivan@agtc.com

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com 

FAQ

What is the significance of the upcoming data release by AGTC on November 11, 2020?

The release will provide 12-month data on the safety and efficacy of AGTC's gene therapy for X-linked Retinitis Pigmentosa, crucial for understanding the treatment's impact.

What is the focus of the Phase 1/2 trial conducted by AGTC?

The trial focuses on evaluating the durability and safety of AGTC's AAV-based gene therapies in patients with X-linked Retinitis Pigmentosa.

How can investors access the AGTC conference call regarding the trial data?

Investors can join the conference call on November 11, 2020, at 8:00 AM ET by dialing 877-407-6184 (US) or 201-389-0877 (international).

What types of diseases is AGTC targeting with its therapies?

AGTC is developing gene therapies for rare ophthalmic, otologic, and central nervous system diseases, with ongoing trials for conditions like XLRP and achromatopsia.

What are the implications of AGTC's clinical trials for the biotechnology market?

The outcomes of AGTC's clinical trials could significantly influence investor confidence and the overall market perception of gene therapies for rare diseases.